# ANTHEM-HFrEF Pivotal Study

Study · id `cardio:ct-nct03425422` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03425422](<https://clinicaltrials.gov/study/NCT03425422>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03425422

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 533 participants.

## Technical summary

Registry record NCT03425422. Randomized; no masking; primary purpose treatment. Start 2018-05-01 (actual); primary completion 2023-05-31 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 533 participants (enrolled count; ClinicalTrials.gov record NCT03425422, source copy `cardio:ctgov-nct03425422-2023-10-10`, retrieved 2026-10-26)
- Started: 2018-05-01 (actual) (ClinicalTrials.gov record NCT03425422, source copy `cardio:ctgov-nct03425422-2023-10-10`, retrieved 2026-10-26)
- Primary completion: 2023-05-31 (actual) (ClinicalTrials.gov record NCT03425422, source copy `cardio:ctgov-nct03425422-2023-10-10`, retrieved 2026-10-26)
- Completion: 2023-05-31 (actual) (ClinicalTrials.gov record NCT03425422, source copy `cardio:ctgov-nct03425422-2023-10-10`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT03425422, source copy `cardio:ctgov-nct03425422-2023-10-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03425422-2023-10-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: ANTHEM-HFrEF Pivotal Study
- Condition: Heart Failure
- Condition: Heart Failure, Congestive
- Condition: Heart Failure, Systolic
- Intervention (Device): VITARIA System
- Lead sponsor: LivaNova
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry condition terms include this condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Registry lists this organization as the lead sponsor: LivaNova (`cardio:org-livanova`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Vagal Nerve Stimulation in Patients With Heart Failure and Reduced Ejection Fraction: The ANTHEM-HFrEF Trial (`cardio:pubmed-42159539`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 084619340b34d4eb271ff47a1cc11fd9e5bc614a42cd06a89c101fbf8f4a8c72
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
